Format

Send to

Choose Destination
PET Clin. 2012 Jul;7(3):263-74. doi: 10.1016/j.cpet.2012.04.003. Epub 2012 May 24.

(18)F NaF PET/CT in the Assessment of Malignant Bone Disease.

Author information

1
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, H-2200, Stanford, CA 94305-5281, USA.

Abstract

Diagnostic imaging plays a major role in the evaluation of patients with malignant bone disease. (18)F-Labeled sodium fluoride ((18)F NaF) is a positron-emitting radiopharmaceutical with desirable characteristics (rapid blood clearance and bone uptake) for high-quality functional imaging of the skeleton. In addition to higher sensitivity and specificity, (18)F NaF PET combined with computed tomography (PET/CT) allows for shorter imaging time, thus improving patients' convenience and benefiting the overall workflow of the imaging facility. Although as yet no robust evidence-based data exist, this article summarizes the published data currently available on the role of (18)F NaF PET/CT in the assessment of malignant bone disease.

PMID:
27157457
DOI:
10.1016/j.cpet.2012.04.003

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center